Home | EndoTODAY | EndoATLAS | Blog


[Propofol ÁøÁ¤ ³»½Ã°æÀ» ´©°¡ ÇÒ °ÍÀΰ¡?]

2015³â 2¿ù 6ÀÏ Áß¾ÓÀϺ¸¿¡ ¸¶Ãë ÀÇ·á»ç°í ºÐ¼®Çغ¸´Ï 'ÇÁ·ÎÆ÷Æú,ºñÀü¹®ÀÇ' - 105¸í Áß 82¸í »ç¸Á. "42.9%´Â Ç¥Áظ¶Ãë °ü¸®¸¸ Ç߾ ¿¹¹æ °¡´ÉÇß´Ù"¶ó´Â ÀÚ±ØÀûÀÎ Á¦¸ñÀÇ ±â»ç°¡ ½Ç·È½À´Ï´Ù. »ï¼º¼­¿ïº´¿ø ¸¶ÃëÅëÁõÀÇÇаú ±è´ö°æ ±³¼ö´ÔÀÇ ÃÖ±Ù ³í¹®À» ¼Ò°³ÇÏ´Â ³»¿ëÀ̾ú½À´Ï´Ù. ¾Æ·¡¿¡ ³í¹® PubMed link¿Í ÃÊ·Ï ¹× ±â»ç Àü¹®À» ¼Ò°³ÇÕ´Ï´Ù.

Analysis of Anesthesia-related Medical Disputes in the 2009-2014 Period Using the Korean Society of Anesthesiologists Database

Using the Korean Society of Anesthesiologists database of anesthesia-related medical disputes (July 2009-June 2014), causative mechanisms and injury patterns were analyzed. In total, 105 cases were analyzed. Most patients were aged < 60 yr (82.9%) and were classified as American Society of Anesthesiologists physical status ¡Â II (90.5%). In 42.9% of all cases, the injuries were determined to be 'avoidable' if the appropriate standard of care had been applied. Sedation was the sec most common type of anesthesia (37.1% of all cases), following by general anesthesia. Most sedation cases (27/39, 69.2%) showed a common lack of vigilance: no pre-procedural testing (82.1%), absence of anesthesia record (89.7%), and non-use of intra-procedural monitoring (15.4%). Most sedation (92.3%) was provided simultaneously by the non-anesthesiologists who performed the procedures. After the resulting injuries were grouped into four categories (temporary, permanent/minor, permanent/major, and death), their causative mechanisms were analyzed in cases with permanent injuries (n=20) and death (n=82). A 'respiratory events' was the leading causative mechanism (56/102, 54.9%). Of these, the most common specific mechanism was hypoxia secondary to airway obstruction or respiratory depression (n=31). The sec most common damaging event was a 'cardiovascular events' (26/102, 25.5%), in which myocardial infarction was the most common specific mechanism (n=12). Our database analysis demonstrated several typical injury profiles (a lack of vigilance in seemingly safe procedures or sedation, non-compliance with the airway management guidelines, and the prevalence of myocardial infarction) and can be helpful to improve patient safety.

±¹³» º´¡¤ÀÇ¿ø¿¡¼­ ÃÖ±Ù 5³â°£ ¸¶Ãë °ü·Ã ÀÇ·á »ç¸Á»ç°í°¡ 82°Ç¿¡ ´ÞÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ƯÈ÷ ºñ±³Àû ¾ÈÀüÇÏ´Ù°í ¿©°ÜÁö´Â ¼ö¸é¸¶Ãë·Î ÀÎÇÑ »ç¸Á»ç°íµµ ÀûÁö ¾Ê¾Ò´Ù. »ï¼º¼­¿ïº´¿ø ¸¶ÃëÅëÁõÀÇÇаú ±è´ö°æ ±³¼ö ¿¬±¸ÆÀÀº 2009³â 7¿ùºÎÅÍ 2014³â 6¿ù±îÁö ±¹³» ÀÇ·á±â°ü¿¡¼­ ¹ß»ýÇÑ ¸¶Ãë °ü·Ã ÀÇ·áºÐÀï Áß ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ°¡ ÀÚ¹®ÇÑ 105°ÇÀ» ºÐ¼®ÇØ ´ëÇÑÀÇÇÐȸ ±¹Á¦ÇмúÁö(JKMS) 2¿ùÈ£¿¡ ¹ßÇ¥Çß´Ù. ¿¬±¸ °á°ú¿¡ µû¸£¸é ÀÌ ±â°£¿¡ ¸¶Ãë °ü·Ã ÀÇ·á»ç°í¸¦ ´çÇÑ È¯ÀÚ 105¸í Áß 82¸í(78.1%)ÀÌ »ç¸ÁÇß´Ù. 60¼¼ ÀÌÇÏ È¯ÀÚ°¡ 82.9%¿´À¸¸ç ÀÌµé °¡¿îµ¥ 90.5%´Â ¹Ì±¹¸¶Ãë°úÇÐȸ ½Åüµî±ÞÁö¼ö 1¶Ç´Â 2ÀÇ °Ç°­ÇÑ »ç¶÷µéÀ̾ú´Ù.

¿¬±¸ÆÀÀº ¡°Àüü 105°Ç Áß 42.9%´Â Ç¥ÁØÀûÀÎ ¸¶Ãë °ü¸®¸¸ Ç߾ ¿¹¹æ °¡´ÉÇÑ °ÍÀ¸·Î ÀÇ·á»ç¾ÈÀ» °¨Á¤ÇÑ ¸¶ÃëÅëÁõÀÇÇаú Àü¹®ÀÇ¿¡ ÀÇÇØ ÆÇÁ¤µÆ´Ù¡±°í ÀüÇß´Ù.¸¶Ãë Á¾·ùº°·Î º¸¸é Àü½Å¸¶Ãë°¡ 50°Ç(47.6%)À¸·Î °¡Àå ¸¹¾Ò´Ù. ¼ö¸é¸¶Ãëµµ 39°Ç(37.1%)À̳ª µÆ´Ù. ¿¬±¸ÆÀÀº ¡°ÁÖ¸ñÇÒ ¸¸ÇÑ ³»¿ëÀº ÀϹÝÀε鿡°Ô Àü½Å¸¶Ãë¿¡ ºñÇØ »ó´ëÀûÀ¸·Î ¾ÈÀüÇÏ´Ù°í ¾Ë·ÁÁ® ÀÖ´Â ¼ö¸é¸¶Ãë°¡ Àüü ÀÇ·Ú °Ç Áß 37.1%¸¦ Â÷ÁöÇÏ°í ÀÖ´Ù´Â Á¡¡±À̶ó°í ¸»Çß´Ù. ƯÈ÷ ¼ö¸é¸¶Ãë »ç°í 39°Ç Áß 30°Ç(76.9%)Àº »ç¸ÁÀ¸·Î À̾îÁ³´Ù. ÀÌ´Â Àü½Å¸¶Ãë »ç°í 50°Ç¿¡¼­ 41°Ç(82.0%)ÀÌ »ç¸ÁÇÑ °Í°ú ºñ½ÁÇÑ ¼öÄ¡´Ù. »ç¸Á ¿øÀÎÀ¸·Î´Â ¼ö¸é¸¶ÃëÁ¦ °ú ¿ë·® ÁÖ»ç·Î ÀÎÇÑ ±âµµÆó¼â ¶Ç´Â È£ÈíºÎÀüÀÌ 24°ÇÀ¸·Î °¡Àå ¸¹¾Ò´Ù.

´õ¿íÀÌ ¼ö¸é¸¶Ãë »ç°íÀÇ 92.3%(36°Ç)´Â ºñ¸¶ÃëÅëÁõÀÇÇаú Àü¹®ÀÇ°¡ ¸¶ÃëÁ¦¸¦ ÁÖ»çÇÑ °æ¿ì¿´´Ù. ¿¬±¸ÆÀÀº "ÀÌ´Â ½Ã¼ú°ú ¹«°üÇÑ µ¶¸³ÀûÀÎ ¼ö¸é ¸¶Ãë Àü´ã ÀÇ·áÁøÀÌ ¹Ýµå½Ã Á¸ÀçÇØ¾ß ÇÑ´Ù´Â ±âº» ÀÓ»óÁöħÀ» ÁöÅ°Áö ¾ÊÀº °Í"À̶ó°í ¼³¸íÇß´Ù. ¶ÇÇÑ ¼ö¸é¸¶ÃëÀÇ 89.7%(35°Ç)¿¡¼­ ÇÁ·ÎÆ÷ÆúÀÌ ´Üµ¶ ¶Ç´Â Ÿ ¾àÁ¦¿Í µ¿¹Ý »ç¿ëµÈ °ÍÀ¸·Î È®ÀεƴÙ. ÀÌ´Â ¹Ì´ÙÁ¹¶÷°ú °°Àº ÀüÅëÀûÀÎ ÁøÁ¤Á¦¿¡ ºñÇØ ÇÁ·ÎÆ÷ÆúÀÌ È£Èí¾ïÁ¦¸¦ ´õ¿í ½ÉÇÏ°Ô À¯¹ßÇÑ´Ù´Â »ç½ÇÀ» ´Ù½Ã ÇÑ ¹ø ÀÔÁõÇÏ´Â »ç·Ê¶ó´Â ºÐ¼®ÀÌ´Ù. ¼ö¸é¸¶Ãë °ü¸®µµ ´ëºÎºÐ ºÎÀûÀýÇÑ °ÍÀ¸·Î Á¶»çµÆ´Ù. 92.3%¿¡¼­ ¸¶Ãë Àü ȯÀÚ Æò°¡±â·ÏÀÌ ¾ø¾úÀ¸¸ç, 98.7%¿¡¼± ¾Æ¿¹¡¡¼ö¸é¸¶Ãë ±â·ÏÁö°¡ ¾ø¾ú´Ù. 6°Ç(15.4%)Àº ¼ö¸é¸¶Ãë Áß È¯ÀÚ °¨½Ã ÀåÄ¡ »ç¿ëÀÌ ÀüÇô ¾ø¾ú°í, 24°Ç(61.5%)ÀÇ °æ¿ì ¼ö¸é¸¶Ãë Áß º¸Á¶ÀûÀÎ »ê¼Ò °ø±ÞÀÌ ¾ø¾ú´Ù.

ÀÌó·³ ¼ö¸é¸¶Ãë¿¡ ´ëÇÑ ³í¶õÀÌ ÀÕµû¸£ÀÚ ¼ö¸é¸¶Ãë¿¡ ´ëÇÑ ±ÔÁ¦¸¦ Àü½Å¸¶Ãë ¼öÁØÀ¸·Î °­È­ÇØ¾ß ÇÑ´Ù´Â ¿©·ÐÀÌ °Å¼¼°Ô ÀÏ°í ÀÖ´Ù. ÇÏÁö¸¸ ÀϺΠºñ¸¶ÃëÅëÁõÀÇÇаú Àü¹®ÀǵéÀº ¹ß²öÇÏ´Â ºÐÀ§±â´Ù. Ÿ°ú ÀÇ»çÀÇ ±ÇÀÍÀ» ħÇØÇÏ´Â ¿ä¼Ò¶ó´Â ÆÇ´Ü¿¡¼­´Ù. ´ëÇÑÆòÀÇ»çȸ´Â ¡°°£´ÜÇÑ ¼ö¸é¸¶Ãëµµ ¸¶Ãë°ú ÀÇ»ç ÀÔȸ ÇÏ¿¡ ÇØ¾ß ÇÑ´Ù´Â ÁÖÀåÀº »ç½Ç»ó Ÿ°ú ÀÇ»çÀÇ ¼ö¸é¸¶ÃëÁ¦ »ç¿ëÀ» Àü¸é ±ÝÇÑ´Ù´Â ¾ê±â¡±¶ó°í ÁöÀûÇß´Ù. ÃÖ±Ù ¼ö¸é¸¶Ãë »ç¸Á»ç°í°¡ ¸î °Ç ÀÖ¾ú´Ù´Â °ÍÀ» ±Ù°Å·Î Ÿ°ú ÀÇ»çÀÇ ÇàÀ§¸¦ ±ÝÁöÇÏ´Â °ÍÀº Æø·ÂÀ̶õ ÁÖÀåÀÌ´Ù. ÆòÀÇ»çȸ´Â ¡°±³Åë»ç°í°¡ ¸î °Ç ÀÖ¾ú´Ù°í ÀÚµ¿Â÷¸¦ ÀüºÎ ¾ø¾ÖÀÚ´Â °Í°ú ¶È°°Àº ¹ß»ó¡±À̶ó¸ç ¡°Å¸°úÀÇ»çÀÇ Á÷¾÷¼öÇàÀÇ ÀÚÀ¯¸¦ Àü¸éÀ¸·Î ħÇØÇÏ´Â ¸¶ÃëÅëÁõÀÇÇаúÀÇ °úº°À̱âÁÖÀǸ¦ °­·ÂÈ÷ ±ÔźÇÑ´Ù¡±°í ÇÇ·ÂÇß´Ù.


[2015-2-8. ÀÌÁØÇà] ¶Ç ÇѹÙÅÁ Å« ½Î¿òÀÌ ¹ú¾îÁú ±â¼¼ÀÔ´Ï´Ù. PropofolÀ» ÀÌ¿ëÇÑ ÁøÁ¤À» ´©°¡ ÇÒ °ÍÀΰ¡ÀÇ ¹®Á¦·Î ½Î¿ì´Â °ÍÀÌÁö¿ä. ±×·±µ¥ Àú´Â ´©°¡ ÇÒ °ÍÀΰ¡´Â º»ÁúÀûÀÎ ¹®Á¦°¡ ¾Æ´Ï¶ó°í »ý°¢ÇÕ´Ï´Ù. ÇÙ½ÉÀº '¾î¶»°Ô ¾ÈÀüÀ» ´ãº¸ÇÒ °ÍÀΰ¡'ÀÔ´Ï´Ù. ´©°¡ Çصµ »ó°ü ¾ø½À´Ï´Ù. ¾ÈÀü¸¸ ÇÏ´Ù¸é...

±â»ç ³»¿ë¿¡ µû¸£¸é "½Ã¼ú°ú ¹«°üÇÑ µ¶¸³ÀûÀÎ ¼ö¸é ¸¶Ãë Àü´ã ÀÇ·áÁøÀÌ ¹Ýµå½Ã Á¸ÀçÇØ¾ß ÇÑ´Ù"´Â ÁÖÀåÀÌ "¸¶Ãë°ú Àǻ縸 propofolÀ» ½á¾ß ÇÑ´Ù"´Â ÁÖÀå°ú µ¿ÀϽõǰí ÀÖ½À´Ï´Ù. ±×·±µ¥ ÀÌ´Â ÀüÇô ´Ù¸¥ À̾߱âÀÔ´Ï´Ù. ÀûÀýÇÑ ±³À°°ú ÃæºÐÇÑ °æÇèÀ» °¡Áø ÀÇ·áÁøÀÌ ½Ã¼ú°ú ¹«°üÇÏ°Ô ÁøÁ¤À» ´ã´çÇÏ¸é µÇ´Â °ÍÀÔ´Ï´Ù. Áï ´Ù¸¥ ÀÏÀº ÇÏÁö ¾Ê°í ¿ÀÁ÷ ÁøÁ¤¸¸ ´ã´çÇÏ´Â »ç¶÷ÀÌ ÀÖ¾î¾ß ÇÑ´Ù´Â °ÍÀÌÁö¿ä. ¸¶Ãë°ú Àǻ翩µµ ÁÁ°í ³»°ú Àǻ翩µµ ÁÁ°í ÀϹÝÀǵµ ÁÁ½À´Ï´Ù. (°£È£»ç ȤÀº °£È£ Á¶¹«»çµµ »ó°ü¾ø´ÂÁö´Â Àú´Â Àß ¸ð¸£°Ú½À´Ï´Ù.) ³»½Ã°æ ½Ã¼úÀ» ÇÏÁö ¾Ê°í ÁøÁ¤¸¸ ´ã´çÇÏ´Â »ç¶÷ÀÌ ÁߴܾøÀÌ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ(uninterrupted continous monitoring)À» ÇÑ´Ù¸é propofol sedationÀº Áö±Ýº¸´Ù ÈξÀ ¾ÈÀüÇØÁú °ÍÀÔ´Ï´Ù. ³»½Ã°æÀ» Çϸ鼭 °¡²û Èú²ý ȯÀÚ »óŸ¦ ÃÄ´Ùº¸´Â °ÍÀº ºÒÃæºÐÇÕ´Ï´Ù. ´©±º°¡ ´Ù¸¥ ÀÏÀ» ÇÏÁö ¾ÊÀ¸¸é¼­ ȯÀÚ°¡ ¿ÏÀüÈ÷ ±ý ¶§±îÁö °è¼Ó ÁöÄѺ¸´Â ÀÇ·áÁøÀÌ ÀÖ¾î¾ß ÇÕ´Ï´Ù. ÀÌ·± ÀÔÀå¿¡¼­ 2³â Àü ¹àÈù ¹Ù ÀÖ´Â ÀúÀÇ position statement´Â ¿©ÀüÈ÷ À¯È¿ÇÕ´Ï´Ù.

* Position statement: Àú´Â ÇÁ·ÎÆ÷ÆúÀ» »ç¿ëÇÑ ³»½Ã°æ ÁøÁ¤¿¡ ¹Ý´ëÇÏÁö ¾Ê½À´Ï´Ù. »çÀü Æò°¡¿Í Áغñ°¡ Àß µÇ¾î¾ßÇϸç, ½Ã¼ú µµÁß ¹× ½Ã¼ú ÈÄ ¸ð´ÏÅ͸µÀÌ ¿øÄ¢´ë·Î ¾ÈÀüÇÏ°Ô ÁøÇàµÇ¾î¾ß ÇÑ´Ù´Â Á¡À» °­Á¶ÇÒ »ÓÀÔ´Ï´Ù. ¾ÈÀü¼ºÀÌ ÃæºÐÈ÷ È®º¸µÇÁö ¸øÇÑ ¾Æ½½¾Æ½½ÇÑ ÁøÁ¤¿¡´Â ¹Ý´ëÇÕ´Ï´Ù. [2013-6-14. ÀÌÁØÇà]

2015³â 2¿ù 8ÀÏ ÇöÀç Á¦°¡ »ý°¢ÇÏ´Â ¹Ù¸¦ ´Ù½Ã Çѹø °£´ÜÈ÷ Á¤¸®Çϸé ÀÌ·¸½À´Ï´Ù. "¿ì¸®³ª¶ó Çö½Ç¿¡¼­ propofolÀ» »ç¿ëÇÑ ¼ö¼úÀ» À§Çؼ­´Â ¸¶Ãë°ú Àǻ簡 ÇÊ¿äÇÕ´Ï´Ù. ±×·¯³ª ªÀº Áø´Ü³»½Ã°æ±îÁö ¸¶Ãë°ú Àǻ簡 ÇÊ¿äÇÏ´Ù°í ÁÖÀåÀº ¹«¸®ÀÔ´Ï´Ù. ¹°·Ð ¸¶Ãë°ú Àǻ簡 ¾ø´õ¶óµµ ÃæºÐÇÑ ¾ÈÀü ´ëÃ¥Àº ÇÊ¿äÁ¶°ÇÀÔ´Ï´Ù."

ÇÑ °¡Áö ´õ. À̹ø ±â»ç¿¡¼­ ¾ð±ÞµÈ ¹Ù¿Í °°ÀÌ propofol ¸¶Ãë »ç°í´Â Àþ°í °Ç°­ÇÑ »ç¶÷¿¡¼­ ¸¹ÀÌ ¹ß»ýÇÕ´Ï´Ù. ½ÉÆó±â´É¿¡ ¹®Á¦°¡ ÀÖ´Â °íÀ§Çè ȯÀÚ¿¡¼­ ¹ß»ýÇÏ´Â °ÍÀÌ ¾Æ´Õ´Ï´Ù. ´ëºÎºÐ ȯÀÚ ¹®Á¦°¡ ¾Æ´Õ´Ï´Ù. Propofol °ú·® Åõ¿©¿Í monitoring ºÎÁ·ÀÌ ¹®Á¦ÀÏ »ÓÀÔ´Ï´Ù. ÀþÀº »ç¶÷¿¡¼­´Â ¿ë·®À» ¿Ã¸®±â ½¬¿ì¹Ç·Î »ç°í°¡ ¸¹Àº °ÍÀÔ´Ï´Ù. ¹æ½ÉÀÌ ¿øÀÎÀ̶ó´Â °ÍÀÌÁö¿ä. µû¶ó¼­ ÀûÀýÈ÷ ÁÖÀÇÇϸé ÈξÀ ´õ ¾ÈÀüÇØ Áú ¼ö ÀÖ½À´Ï´Ù.


[2015-2-9. ÀÌÁØÇà] À̹ø ±â»ç¿Í ±×¿¡ ´ëÇÑ ÀúÀÇ ÀÇ°ßÀ» ÇÑ ¸¶Ãë°ú ¼±»ý´Ô²² º¸¿©µå·È°í ¾Æ·¡¿Í °°Àº ´äº¯À» ¹Þ¾Ò½À´Ï´Ù. ¸¶Ãë°ú ¼±»ý´ÔµéÀº ´Ù¸¥ Àü°ø ¼±»ý´ÔµéÀÇ propofol »ç¿ë¿¡ ¹Ý´ëÇÏÁö ¾Ê´Â´Ù°í ÇÕ´Ï´Ù. Àü¹®°¡·Î¼­ ¾ÈÀüÀ» À§ÇÑ ÃÖ¼ÒÇÑÀÇ °¡À̵å¶óÀÎÀ» ÁöÅ°µµ·Ï ±Ç°íÇÏ°í ÀÖÀ» »ÓÀÎ µí ÇÕ´Ï´Ù. ´ÜÁö ¸¶Ãë Àü¹®°¡°¡ ½Ã¼ú¿¡ Âü¿©ÇÒ ¶§¿¡´Â µû·Î ¼ö°¡¸¦ Àû¿ëÇÏÀÚ´Â °ÍÀ̾ú½À´Ï´Ù. Àú´Â ¸¶Ãë°úÀÇ ÀÔÀå¿¡ ¿ø·ÐÀûÀ¸·Î Âù¼ºÇÕ´Ï´Ù. Àü¹®°¡ÀÇ °æÇè°ú ³ë·ÂÀº Á¸ÁßÇØÁÖ´Â °ÍÀÌ ¸Â±â ¶§¹®ÀÔ´Ï´Ù. ´Ù¸¸ "°£È£»ç"·Î ¸í½ÃµÈ ºÎºÐÀÌ Àֱ⠶§¹®¿¡ "°£È£º¸Á¶»ç"°¡ ÁÖ ÀηÂÀÎ °³¾÷°¡ ¼±»ý´ÔµéÀÇ ¹Ý´ë°¡ ¿¹»óµË´Ï´Ù. ¸¶Ãë°ú ¼±»ý´ÔÀÇ ÀÇ°ßÀ» ¾Æ·¡¿¡ ¿Å±é´Ï´Ù.

[2015-2-9. ¸¶Ãë°ú ¼±»ý´ÔÀÇ ´äº¯]

´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸÀÇ ÀÔÀåÀº ¾Æ·¡¿Í °°½À´Ï´Ù.

1. ÇÁ·ÎÆ÷Æú ¼ö¸é¸¶Ãë´Â Ÿ ÁøÁ¤Á¦ »ç¿ë ¼ö¸é¸¶Ãë¿Í ºÐ¸®ÇÏ¿© Àü½Å¸¶Ãë¿¡ ÁØÇÏ´Â °ü¸®°¡ ÇÊ¿äÇÏ´Ù.

2. ÇÁ·ÎÆ÷Æú ¼ö¸é¸¶Ãë ½Ã´Â ¹Ýµå½Ã "½Ã¼ú°ú ¹«°üÇÑ µ¶¸³ÀûÀÎ ¼ö¸é ¸¶Ãë Àü´ã ÀÇ·áÁø(¼ÒÁ¤ÀÇ ±³À°À» ¹ÞÀº ÀÇ»ç ¶Ç´Â °£È£»ç)"ÀÌ ¹Ýµå½Ã Á¸ÀçÇØ¾ß ÇÑ´Ù.

¸¶ÃëÅëÁõÀÇÇаú Àü¹®ÀǸ¸ÀÌ ÇÁ·ÎÆ÷Æú ÁøÁ¤À» Çؾ߸¸ ÇÑ´Ù´Â °ÍÀº ÀúÈñ ÀÔÀåÀÌ ¾Æ´Õ´Ï´Ù. ´Ù¸¸ ¸¶ÃëÅëÁõÀÇÇаú Àü¹®ÀÇ°¡ ÇÁ·ÎÆ÷Æú ÁøÁ¤À» ÇÒ °æ¿ì °¡Àå optimalÇϹǷÎ, ÀÌ°Ô °¡´ÉÇϵµ·Ï MAC (Monitored Anesthesia Care) ¼ö°¡¸¦ ½Å¼³ÇØ´Þ¶ó´Â °ÍÀÔ´Ï´Ù.

ÃÖÁ¾ ÇÁ·ÎÆ÷Æú ÁøÁ¤ÀÇ ÁÖü ¼±ÅÃÀº ȯÀÚÀÇ ¼±ÅÃÀÇ ¸òÀ¸·Î ¸Ã±âÀÚ´Â °ÍÀÔ´Ï´Ù. µ·À» ´õ ³»°í(½Å¼³µÉ MAC ¼ö°¡·Î) ¸¶ÃëÅëÁõÀÇÇаú Àǻ翡°Ô ¹ÞµçÁö ¾Æ´Ï¸é ¾Æ´Ï¸é ÇöÇà ¼ö°¡´ë·Î Ÿ°ú Àǻ翡°Ô ¹ÞµçÁö. ¹°·Ð ÀÌ °æ¿ìµµ ÇÁ·ÎÆ÷Æú¿¡ ÇÑÇؼ­´Â ÇöÀçó·³ ÁøÁ¤ µ¿ÀǼ­/±â·ÏÁö/ȸº¹ °ü¸®Áö, ÁøÁ¤ Áß ÀûÀýÇÑ °¨½Ã, µ¶¸³µÈ ÁøÁ¤ °ü¸® ÀÇ·áÁø ¾øÀÌ´Â Çؼ­´Â ¾È µÇ°ÚÁÒ. »ç½Ç ¹Ì±¹ FDA, ¹Ì±¹ ¹× À¯·´ ¸¶Ãë°úÇÐȸÀÇ °ø½Ä ÀÔÀåÀº ÇÁ·ÎÆ÷Æú ÁøÁ¤Àº ¸¶Ãë°ú Àǻ縸ÀÌ ÇØ¾Æ ÇÑ´Ù´Â °ÍÀÌÁö¸¸ ÀúÈñ ½ÇÁ¤ »ó ÀÌ°ÍÀº ¹«¸®°¡ ÀÖ¾î º¸ÀÔ´Ï´Ù.


[2015-2-9. ¸¶Ãë°ú ¼±»ý´ÔÀÇ Ãß°¡ ´äº¯]

ÇÐȸ ÀÔÀåÀÌ Àß Àü´ÞµÈ °Í °°½À´Ï´Ù. '°£È£Á¶¹«»ç ¹èÁ¦' ºÎºÐÀº °³¿ø°¡ÀÇ Çö½ÇÀº ¾ËÁö¸¸, ÇâÁ¤½Å¼ºÀǾàÇ°À¸·Î ºÐ·ùµÈ ÇÁ·ÎÆ÷Æú Áֻ縦 ¾Æ¹«¸® Àǻ簡 Áö½Ã, °¨µ¶ÇÏ´õ¶óµµ °£È£Á¶¹«»ç°¡ ÁÖ»çÇϵµ·Ï ÇÑ´Ù´Â °ÍÀº ÀÇ·á¹ý À§¹ÝÀÔ´Ï´Ù. ¶ÇÇÑ ÁøÁ¤ Áß È¯ÀÚ °¨½Ã¸¸ º¸´õ¶óµµ °£È£Á¶¹«»çÀÇ ¾÷¹« ¹üÀ§¸¦ ³Ñ¾î¼­´Â ¾÷¹«¿µ¿ªÀÔ´Ï´Ù(¿ª½Ã ÀÇ·á¹ý À§¹ÝÀÌ¸ç ¿Ü±¹ÀÇ À¯»ç ±ÔÁ¤µµ ¾ø½À´Ï´Ù).


[Âü°íÀÚ·á]

0. ÁøÁ¤ ÇÕº´Áõ (complications of sedation) - ÁøÁ¤³»½Ã°æ, ¼ö¸é³»½Ã°æ, ¹Ì´ÙÁ¹¶÷, ÇÁ·ÎÆ÷Æú

1. ±¹°ú¼ö ȤÀº °ü·Ã ´Üü¿¡¼­ Á¦½ÃÇÑ ÅëÇÕ ÀÚ·á

2. ³»½Ã°æ ÁøÁ¤ »ç¸Á »ç·Ê

3. ³»½Ã°æ ÀÌ¿Ü »ç¸Á »ç·Ê

4. ´Ù¾çÇÑ »ç°í - ¼ºÆøÇà, ±³Åë»ç°í, ³«»ó, Áßµ¶

5. ¿¬¿¹Àΰú ÁøÁ¤

6. ÀÇ·á±â°ü °ü·Ã

7. ±âŸ

8. ÇÁ·ÎÆ÷Æú º¸°ü ¹× Ãë±Þ½Ã ÁÖÀÇÁ¡

9. ÇÁ·ÎÆ÷Æú °ü·Ã EndoTODAY

10. ¾Öµ¶ÀÚ ÀÇ°ß

© ÀÌÁØÇà